4.7 Article

Discovery of the Potent and Highly Selective PARP7 Inhibitor as a Novel Immunotherapeutic Agent for Tumors

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Chemistry, Medicinal

Medicinal Chemistry Perspective on Targeting Mono-ADP-Ribosylating PARPs with Small Molecules

Maria Giulia Nizi et al.

Summary: Major advances have been made in defining functions for human mono-ADP-ribosylating PARP enzymes (mono-ARTs), opening up potential applications for treating diseases. The combination of structural biology and medicinal chemistry has led to the development of potent small molecule inhibitors that bind to the catalytic domain. Most of these inhibitors are still in the early stages, but some have shown promising profiles as chemical tools. A compound targeting PARP7 has even progressed to clinical trials.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

Review Medicine, Research & Experimental

Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance

Sreya Bagchi et al.

Summary: This article highlights the significance of immune checkpoint inhibitors in cancer immunotherapy and the research findings on the changes in local and systemic immune cells after treatment. It emphasizes the need for understanding the requirements for an effective and safe antitumor immune response following ICI therapy.

ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 16, 2021 (2021)

Article Biology

Identification of PARP-7 substrates reveals a role for MARylation in microtubule control in ovarian cancer cells

Lavanya H. Palavalli Parsons et al.

Summary: PARP-7, a mono(ADP-ribosyl) transferase, plays a role in ovarian cancer cells by influencing cell growth and migration. Through MARylation of alpha-tubulin, it promotes microtubule instability to regulate cell growth and motility, with implications in cancer-related cellular phenotypes.
Article Biology

Chemical genetics and proteome-wide site mapping reveal cysteine MARylation by PARP-7 on immune-relevant protein targets

Kelsie M. Rodriguez et al.

Summary: PARP-7 has been identified as an important regulator of the innate immune response, with a key target being the inactive PARP family member PARP-13. Specifically, PARP-7 preferentially MARylates cysteine residues in the RNA binding zinc finger domain of PARP-13, as revealed by proteome-wide ADP-ribosylation analysis.
Article Cell Biology

PARP7 and Mono-ADP-Ribosylation Negatively Regulate Estrogen Receptor α Signaling in Human Breast Cancer Cells

Marit Rasmussen et al.

Summary: PARP7 is a mono-ADP-ribosyltransferase involved in various cellular processes, including regulation of estrogen receptor alpha signaling. PARP7 mono-ADP-ribosylates estrogen receptor alpha, potentially playing a significant role in estrogen receptor positive breast cancer.
Review Cell Biology

MARTs and MARylation in the Cytosol: Biological Functions, Mechanisms of Action, and Therapeutic Potential

Sridevi Challa et al.

Summary: MARylation is a regulatory post-translational modification of proteins that controls their functions through various mechanisms; the biological roles of MARTs and the development of therapeutic drugs are not well understood; new technologies are revealing the essential roles of MARTs in regulating cellular processes.
Article Oncology

PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity

Joseph M. Gozgit et al.

Summary: PARP7 is a monoPARP that negatively regulates nucleic acid sensing in tumor cells. Inhibition of PARP7 restores type I interferon signaling responses, inhibits cell proliferation, activates the immune system, and induces tumor regression. The PARP7 inhibitor RBN-2397 shows promising therapeutic effects in lung cancer models and induces tumor-specific adaptive immune memory.

CANCER CELL (2021)

Review Biotechnology & Applied Microbiology

Poly(ADP-ribose) polymerase inhibition: past, present and future

Nicola J. Curtin et al.

NATURE REVIEWS DRUG DISCOVERY (2020)

Review Chemistry, Medicinal

Small-Molecule Immuno-Oncology Therapy: Advances, Challenges and New Directions

Shulun Chen et al.

CURRENT TOPICS IN MEDICINAL CHEMISTRY (2019)

Review Biotechnology & Applied Microbiology

Interferons α and β in cancer: therapeutic opportunities from new insights

Ernest C. Borden

NATURE REVIEWS DRUG DISCOVERY (2019)

Review Multidisciplinary Sciences

Emerging roles of eraser enzymes in the dynamic control of protein ADP-ribosylation

Julia O'Sullivan et al.

NATURE COMMUNICATIONS (2019)

Review Immunology

STING pathway agonism as a cancer therapeutic

Blake A. Flood et al.

IMMUNOLOGICAL REVIEWS (2019)

News Item Medicine, General & Internal

The Promise and Challenges of CAR-T Gene Therapy

Bridget M. Kuehn

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)

Review Oncology

Building better monoclonal antibody-based therapeutics

George J. Weiner

NATURE REVIEWS CANCER (2015)

Article Multidisciplinary Sciences

A systematic analysis of the PARP protein family identifies new functions critical for cell physiology

Sejal Vyas et al.

NATURE COMMUNICATIONS (2013)

Review Multidisciplinary Sciences

Cancer immunotherapy comes of age

Ira Mellman et al.

NATURE (2011)

Review Biochemistry & Molecular Biology

Toward a unified nomenclature for mammalian ADP-ribosyltransferases

Michael O. Hottiger et al.

TRENDS IN BIOCHEMICAL SCIENCES (2010)

Review Biochemistry & Molecular Biology

The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases

Paul O. Hassa et al.

FRONTIERS IN BIOSCIENCE-LANDMARK (2008)

Article Biochemistry & Molecular Biology

Cancer immunotherapy: moving beyond current vaccines

SA Rosenberg et al.

NATURE MEDICINE (2004)